Clinical and virological features of occult hepatitis B in patients with HBsAg seroclearance post-treatment or spontaneously

Liver International

Volumn 34, Issue 6, 2014, Pages

  Cheng, Huei Ru ^a   Kao, Jia Horng ^a,b   Wu, Hui Lin ^a,b   Chen, Ting Chih ^a   Tseng, Tai Chung ^c   Liu, Chen Hua ^b   Su, Tung Hung ^b   Chen, Pei Jer ^a,b   Chen, Ding Shinn ^a,b   Liu, Chun Jen ^a,b  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^c BUDDHIST TZU CHI GENERAL HOSPITAL   (Taiwan)

Author keywords

Clearance; Mutation; Occult hepatitis B; Spontaneous HBsAg loss

Indexed keywords

ADEFOVIR DIPIVOXIL; ENTECAVIR; HEPATITIS B SURFACE ANTIGEN; LAMIVUDINE; MEMBRANE PROTEIN; PEGINTERFERON ALPHA2A PLUS RIBAVIRIN; VIRUS DNA; ALPHA INTERFERON; ANTIVIRUS AGENT; BIOLOGICAL MARKER; MACROGOL DERIVATIVE; PEGINTERFERON ALPHA2A; RECOMBINANT PROTEIN; RIBAVIRIN; S ENVELOPE PROTEIN, HEPATITIS B VIRUS; VIRUS ENVELOPE PROTEIN;

ADULT; AMINO ACID SEQUENCE; ANTIVIRAL THERAPY; ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GENE MUTATION; GENETIC ASSOCIATION; HEPATITIS B; HEPATITIS C; HUMAN; IN VITRO STUDY; MALE; MIXED INFECTION; NUCLEOTIDE SEQUENCE; OCCULT HEPATITIS B; PREVALENCE; PROMOTER REGION; STOP CODON; TRANSCRIPTION INITIATION; VIRUS REPLICATION; WILD TYPE; BLOOD; CELL LINE; CROSS-SECTIONAL STUDY; DRUG COMBINATION; DRUG EFFECTS; GENETIC TRANSFECTION; GENETICS; GENOTYPE; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; IMMUNOLOGY; MIDDLE AGED; MUTATION; PHENOTYPE; TAIWAN; TIME; TREATMENT OUTCOME; VIRUS LOAD;

ADULT; ANTIVIRAL AGENTS; BIOLOGICAL MARKERS; CELL LINE; CROSS-SECTIONAL STUDIES; DNA, VIRAL; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; INTERFERON-ALPHA; MALE; MIDDLE AGED; MUTATION; PHENOTYPE; POLYETHYLENE GLYCOLS; PREVALENCE; PROMOTER REGIONS, GENETIC; RECOMBINANT PROTEINS; RIBAVIRIN; TAIWAN; TIME FACTORS; TRANSFECTION; TREATMENT OUTCOME; VIRAL ENVELOPE PROTEINS; VIRAL LOAD;

EID: 84902550723     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/liv.12324     Document Type: Article

References (35)

1. Liaw YF, Chu CM. Hepatitis B virus infection. Lancet 2009; 373: 582-92.
2. Kao JH, Chen DS. Global control of hepatitis B virus infection. Lancet Infect Dis 2002; 2: 395-403.
3. Chen YC, Sheen IS, Chu CM, et al. Prognosis following spontaneous HBsAg seroclearance in chronic hepatitis B patients with or without concurrent infection. Gastroenterology 2002; 123: 1084-9.
4. Chu CM, Liaw YF. Hepatitis B surface antigen seroclearance during chronic HBV infection. Antivir Ther 2010; 15: 133-43.
5. Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology 2007; 45: 507-39.
6. Liaw YF, Chen YC, Sheen IS, et al. Impact of acute hepatitis C virus superinfection in patients with chronic hepatitis B virus infection. Gastroenterology 2004; 126: 1024-9.
7. Tseng FC, Edlin BR, Zhang M, et al. The inverse relationship between chronic HBV and HCV infections among injection drug users is associated with decades of age and drug use. J Viral Hepat 2008; 15: 690-8.
8. Hsu CW, Yeh CT, Chang ML, et al. Identification of a hepatitis B virus S gene mutant in lamivudine-treated patients experiencing HBsAg seroclearance. Gastroenterology 2007; 132: 543-50.
9. Loriot MA, Marcellin P, Bismuth E, et al. Demonstration of hepatitis B virus DNA by polymerase chain reaction in the serum and the liver after spontaneous or therapeutically induced HBeAg to anti-HBe or HBsAg to anti-HBs seroconversion in patients with chronic hepatitis B. Hepatology 1992; 15: 32-6.
10. Marcellin P, Martinot-Peignoux M, Loriot MA, et al. Persistence of hepatitis B virus DNA demonstrated by polymerase chain reaction in serum and liver after loss of HBsAg induced by antiviral therapy. Ann Intern Med 1990; 112: 227-8.
11. EASL Clinical Practice Guidelines. Management of chronic hepatitis B virus infection. J Hepatol 2012; 57: 167-85.
12. Liaw YF, Leung N, Kao JH, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update. Hepatol Int 2012; 6: 531-61, updated.
13. Brunetto MR, Moriconi F, Bonino F, et al. Hepatitis B virus surface antigen levels: a guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B. Hepatology 2009; 49: 1141-50.
14. Liu CJ, Chuang WL, Lee CM, et al. Peginterferon alfa-2a plus ribavirin for the treatment of dual chronic infection with hepatitis B and C viruses. Gastroenterology 2009; 136: 496-504.
15. Kao JH, Chen PJ, Lai MY, et al. Sequence analysis of pre-S/surface and pre-core/core promoter genes of hepatitis B virus in chronic hepatitis C patients with occult HBV infection. J Med Virol 2002; 68: 216-20.
16. Hollinger FB, Sood G. Occult hepatitis B virus infection: a covert operation. J Viral Hepat 2010; 17: 1-15.
17. Raimondo G, Allain JP, Brunetto MR, et al. Statements from the Taormina expert meeting on occult hepatitis B virus infection. J Hepatol 2008; 49: 652-7.
18. Liu CJ, Kao JH, Wang HY, et al. Origin of serum hepatitis B virus in acute exacerbation: comparison with HBV in the liver and from other exacerbation. Hepatology 2004; 40: 310-7.
19. Tian Y, Xu Y, Zhang Z, et al. The amino acid residues at positions 120 to 123 are crucial for the antigenicity of hepatitis B surface antigen. J Clin Microbiol 2007; 45: 2971-8.
20. Chen SH, Wu H, Kao JH, et al. Persistent hepatitis B viral replication in a FVB/N mouse model: impact of host and viral factors. PLoS ONE 2012; 7: e36984.
21. Wu HL, Huang LR, Huang CC, et al. RNA interference-mediated control of hepatitis B virus and emergence of resistant mutant. Gastroenterology 2005; 128: 708-16.
22. Wursthorn K, Lutgehetmann M, Dandri M, et al. Peginterferon alpha-2b plus adefovir induce strong cccDNA decline and HBsAg reduction in patients with chronic hepatitis B. Hepatology 2006; 44: 675-84.
23. Sheen IS, Liaw YF, Chu CM, et al. Role of hepatitis C virus infection in spontaneous hepatitis B surface antigen clearance during chronic hepatitis B virus infection. J Infect Dis 1992; 165: 831-4.
24. Cacciola I, Pollicino T, Squadrito G, et al. Occult hepatitis B virus infection in patients with chronic hepatitis C liver disease. New Engl J Med 1999; 341: 22-6.
25. Chen SY, Kao CF, Chen CM, et al. Mechanisms for inhibition of hepatitis B virus gene expression and replication by hepatitis C virus core protein. J Biol Chem 2003; 278: 591-607.
26. Hiraga N, Imamura M, Hatakeyama T, et al. Absence of viral interference and different susceptibility to interferon between hepatitis B virus and hepatitis C virus in human hepatocyte chimeric mice. J Hepatol 2009; 51: 1046-54.
27. Zerbini A, Pilli M, Boni C, et al. The characteristics of the cell-mediated immune response identify different profiles of occult hepatitis B virus infection. Gastroenterology 2008; 134: 1470-81.
28. Vivekanandan P, Kannangai R, Ray SC, et al. Comprehensive genetic and epigenetic analysis of occult hepatitis B from liver tissue samples. Clin Infect Dis 2008; 46: 1227-36.
29. Raimondo G, Pollicino T, Cacciola I, et al. Occult hepatitis B virus infection. J Hepatol 2007; 46: 160-70.
30. Hsu CW, Yeh CT. Emergence of hepatitis B virus S gene mutants in patients experiencing hepatitis B surface antigen seroconversion after peginterferon therapy. Hepatology 2011; 54: 101-8.
31. Schüttler CG, Fiedler N, Schmidt K, et al. Suppression of hepatitis B virus enhancer 1 and 2 by hepatitis C virus core protein. J Hepatol 2002; 37: 855-62.
32. Kamatani Y, Wattanapokayakit S, Ochi H, et al. A genome-wide association study identifies variants in the HLA-DP locus associated with chronic hepatitis B in Asians. Nat Genet 2009; 41: 591-5.
33. Wursthorn K, Buggisch P, Lutgehetmann M, et al. Temporary HBV resolution in an HIV-coinfected patient during HBV-directed combination therapy followed by relapse of HBV. Antivir Ther 2006; 11: 647-52.
34. Tseng TC, Liu CJ, Su TH, et al. Serum hepatitis B surface antigen levels predict surface antigen loss in hepatitis B e antigen seroconverters. Gastroenterology 2011; 141: 517-25.
35. Tseng TC, Liu CJ, Yang HC, et al. Determinants of spontaneous surface antigen loss in hepatitis B e antigen-negative patients with a low viral load. Hepatology 2012; 55: 68-76.